Nicolas Castillo’s Post

University College London Researchers Develop Carbon Beads That Slow the Progress of Liver Disease and Improve Gut Microbiome As this therapeutic approach gains regulatory approval, clinical laboratory tests to determine condition of patient’s gut microbiota and monitor therapy will be needed Some developments in the clinical laboratory industry are less about diagnostic tests and more about novel approaches to therapy. Such is the case with a new carbon bead technology developed by researchers from University College London (UCL) and the Royal Free Hospital intended to remove harmful bacteria toxins from the gut before they leak to the liver. The macroporous beads, which come in small pouches, are delivered orally and could be utilized in the future to treat a number of diseases. Why is this relevant? Once a new treatment is accepted for clinical use, demand increases for a clinical laboratory test that confirms the therapy will likely work and to monitor its progress. In collaboration with Yaqrit, a UK-based life sciences company that develops treatments for chronic liver disease, the UCL and Royal Free Hospital scientists engineered the carbon beads—known as CARBALIVE—to help restore gut health. They measured the technology’s impact on liver, kidney, and brain function in both rats and... Read the Dark Daily article at https://hubs.ly/Q02LLKD_0

I am grateful and proud to announce the publication of my study, which links proteins and metabolites to atrial fibrillation and heart failure. Thanks to the wonderful guidance and collaboration of Chris Finan, Sandesh Chopade, Rui Providência, Connie Bezzina, Folkert Asselbergs, Jessica van Setten, and Amand Floriaan Schmidt from UCL Institute of Cardiovascular Science, Amsterdam Cardiovascular Sciences, Amsterdam UMC Hartcentrum , UCL Institute of Health Informatics, and Circulatory Health UMC Utrecht. The 38 proteins and 35 metabolites that we relate to cardiac diseases could provide new directions for treatments. The proteins are all possible drug targets, but some of them are already targeted by drugs. These are of special interest, because these existing drugs may be altered to benefit the heart. Read more in the full article: https://lnkd.in/eePHStpH #genetics #circulatoryhealth #cardiacdisease

#News 🎉Nature Publishes: Inhibition of IL-11 signaling extends mammalian healthspan and lifespan Yesterday, Professor Stuart A. Cook from the Duke-NUS Medical School in Singapore published the article Inhibition of IL-11 signalling extends mammalian healthspan and lifespan in Nature. Deletion of Il11 or Il11ra1 protects against metabolic decline, multi-morbidity and frailty in old age. In lifespan studies, genetic deletion of Il11 extended the lives of mice of both sexes, by 24.9% on average. These results demonstrate a role for the pro-inflammatory factor IL-11 in mammalian healthspan and lifespan.  Anti-IL-11 therapy, which is currently in early-stage clinical trials for fibrotic lung disease, may provide a translational opportunity to determine the effects of IL-11 inhibition on ageing pathologies in older people. 👉learn more about our IL-11 research products! https://lnkd.in/gvBz7iMj 📧 mkt.genomeditech@gmail.com  #antibodydiscovery #antibodytherapeutics #celllinedevelopment #cancertreatment #antibodies #drugdiscovery #breakthrough #IL-11 Fig: Genetic or pharmacologic inhibition of IL-11 extends life expectancy of male and female mice.

Genomic Data is Used in Person-Centered Medicine to Enhance Diagnosis by Focusing on the Immune System Abstract Genomic data is crucial for precise treatment, known as customized medicine. Its use in treating autoimmune diseases will lead to a significant advancement in medicine. Autoimmune illnesses occur when the body’s immune response identifies and reacts to self-antigens. Various methods may incorporate precision medical data into the clinical care of autoimmune disorders, such as identification, prognosis, classification, and prediction of therapy reactions. Various indicators are available to assist in clinical decision-making, with other indicators currently being discovered and suggested. This article focuses on information and databases in personalized medicine for autoimmune medical conditions and exchanging information. The discussion focused on personalized medicine for specific autoimmune disorders, examining different indicators for identification, prognosis, classification, and treatment response tracking. www.ATJournal.ir

Small study shows abnormal immune-cell activity with #longCOVID Story on Center for Infectious Disease Research and Policy (CIDRAP) Study in Science Translational Medicine #COVID19 #COVID19Aus https://lnkd.in/dwWhhrq4

Our latest accepted abstract of our unpublished work on the association of mitochondrial LonP1 upregulation in end-stage HF patients with clinical outcome pre and post LVAD intervention is now out in Circulation. Although the exact mechanisms of this association is yet to be tested in human invitro models, it still adds to the pre-existing notion of the therapeutic potential of targeting mitochondrial function in human end-stage HF. Yasmine A. Ayman Maher https://lnkd.in/eT_rYfZs.

I’d like to share our recent publication regarding multivisceral transplant and the impact of HLA specific antibodies. British Society for Histocompatibility and Immunogenetics (BSHI)

Introduction to a deep analysis of Abbas et al; all molecular mechanisms in our fight against pathogens, tumors, foreign tissue and the rest. Written in the age of pandemics and tricky evolving viruses. Yours Truly, Dr. Milan **Founder and CEO of MediMastery - A company dedicated to resolving the evolving issues of medical education in the era of pandemics, tricky viruses and gigatronic masses of evolving medical data https://lnkd.in/e2uENCTX #immunology #abbas #lichtman #covid19pandemic #pandemic #bookreview #medicaltextbook #medicaleducation #molecularbiology #molecular #immunesystem #immunity

reMYND NV announces the publication in the prestigious journal Science of research detailing the identification of first-in-class small-molecule septin modulators with neuroprotective efficacy. 2 key takeaways: 👉 reMYND’s septin modulator program demonstrated neuroprotective qualities in Alzheimer’s disease models  👉 the findings provide support for deregulated calcium signalling as a key-driver of neurodegeneration 

Congenital Hyperinsulinism in Humans and Insulin Secretory Dysfunction in Mice Caused by Biallelic DNAJC3 Variants In a recent collaborative effort, we describe the relevance of DNAJC3 as #disease -causing #gene in #patients with hyperinsulinemic hypoglycaemia (HH). Our findings highlight the importance of clinicians screening for HH in DNAJC3 deficiency and consider DNAJC3 variants in the differential diagnosis of congenital hyperinsulinism (CHI). CHI is a rare genetic disorder that causes recurrent episodes of HH and is a component of various rare #genetic syndromes (e.g. #overgrowth syndromes, chromosomal and monogenic developmental syndromes, congenital disorders of #glycosylation, syndromic #channelopathies). The genetic and molecular mechanisms of CHI are diverse. This report presents a #casestudy of an individual with HH caused by DNAJC3 variants, a gene whose biallelic variants cause a multisystem disease, including early-onset diabetes mellitus. The study demonstrates that HH may be a primary symptom of DNAJC3 deficiency and can persist until adolescence. Furthermore, the findings suggest that uncontrolled calcium flux from the ER to the cytosol is the most likely mechanism triggering insulin release in DNAJC3 deficiency. This is the first genetic mechanism explaining HH solely by the disruption of intracellular calcium homeostasis. Our collaborative effort highlights the importance of close interactions between #academia and the private sector as fruitful and complementary. The #publication can be found here: https://lnkd.in/ey9hdEWQ #medizinischegenetikmainz #genetics #genetictesting